On the clinical impact of cerebral dopamine D2 receptor scintigraphy;Zur klinischen wertigkeit der zerebralen dopamin-D2 rezeptorszintigraphie

NuklearMedizin

Volumn 37, Issue 7, 1998, Pages 245-250

  Larisch, R ^a   Klimke, A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Dopamine; Dopamine D2 receptor; Neurology; PET; Psychiatry; Review; SPECT

Indexed keywords

BUTYROPHENONE DERIVATIVE; DOPAMINE 2 RECEPTOR; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE;

BRAIN SCINTISCANNING; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; HUMAN; ISOTOPE LABELING; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PROGRESSIVE SUPRANUCLEAR PALSY; RECEPTOR BINDING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0031787256     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1632342     Document Type: Review

References (58)

1. Antonini A, Schwarz J, Oertel WH et al. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994; 44: 1325-9.
2. Antonini A, Vontobel P, Psylla M et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995; 52: 1183-90.
3. Arnett CD, Shiue CY, Wolf AP et al. Comparison of three 18F-labeled butyrophenone neuroleptic drugs in the baboon using positron emission tomography. J Neurochem 1985; 44: 835-44.
4. Boy C, Klimke A, Holschbach M et al. Imaging dopamine-D4-receptors in the living primate brain: A positron emission tomography study using the novel D1-/D4-antagonist [11C]SDZ GLC 756. Synapse 1998: im Druck.
5. Bruecke T, Woeber C, Podreka I et al. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects A SPECT study. J Cereb Blood Flow Metab 1995; 15: 513-8.
6. Buchali K, Flade H, Johannsen B et al. A preclinical study of the organ distribution and radiation dosage of radioiodinated iodolisuride. Nuklearmedizin 1991; 30: 137-40.
7. D'haenen HA, Bossuyt A, Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 1994; 35: 128-32.
8. Diehl DJ, Gershon S. The role of dopamine in mood disorders. Compr Psychiatry 1992; 33: 115-20.
9. Ebert D, Feistel H, Kaschka W et al. Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation - preliminary results. Biol Psychiatry 1994; 35: 880-5.
10. Ehrin E, Farde L, Depaulis T et al. Preparation of 11C-labelled raclopride. a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in monkey. Int J Appl Radiat Isot 1985; 36: 269-73.
11. Farde L, Ehrin E, Eriksson L et al. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci USA 1985; 82: 3863-7
12. Farde L, Hall H, Ehrin E et al. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986; 231: 258-61
13. Farde L, Nordstrom AL, PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry Suppl 1992; 30-3.
14. Farde L, Wiesel FA, Stone-Elander S et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients - a positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 1990; 47: 213-9.
15. Fornaguera J, Huston JP, Carey RJ. Stimulation of D1- or D2-receptors in drug-naive rats with different degrees of unilateral nigro-striatal dopamine lesions. Psychopharmacologv 1995; 119: 145-54.
16. Fowler JS, Arnett CD, Wolf AP et al. 11C-spiroperidol: synthesis, specific activity determination, and biodistribution in mice. J Nucl Med 1982; 23: 437-45
17. Hall H, Sedvail G, Magnusson O et al. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 1994; 11: 245-56.
18. Hierholzer J, Cordes M, Schelosky L et al. Bestimmung der zerebralen Dopamin-(D2)-Rezeptoren-Dichte mit Hilfe der 123Jod-IB-ZM-SPECT bei Patienten mit Morbus Parkinson. Roefo 1992; 157: 390-8.
19. Ichise M, Toyama H, Fornazzari L et al. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. J Nucl Med 1993; 34: 1274-81.
20. Jauss M, Krack P, Franz M et al. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome. Mov Disord 1996; 11: 126-8.
21. Kessler RM, Ansari MS, Schmidt DE et al. High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride. a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. Life Sci 1991, 49: 617-28.
22. Klimke A, Klieser E. Catatoma. Current therapeutic recommendations. CNS Drugs 1994; 2: 280-91.
23. Klimke A, Klieser E. Das atypische Neuroleptikum Clozapin (Leponex) - aktueller Kenntnisstand und neuere klinische Aspekte. Fortschr Neurol Psychiatr 1995; 63: 173-93.
24. Klimke A, Larisch R, Janz A et al. Dopamine D2 receptor binding before and after treatment of major depression measured by single photon emission computed tomography. Psychiatry Res Neuroimaging 1998; im Druck.
25. Kuikka JT, Akerman KK, Hiltunen J et al. Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride SPET. Eur J Nucl Med 1997; 24: 483-7.
26. Kung HF, Pan S, Kung MP et al. In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med 1989; 30: 88-92.
27. Larisch R, Klimke A, Vosberg H et al. in vivo evidence for the involvement of dopamine-D2 receptors in striatum and anterior cingulate gyrus in major depression. NeuroImage 1997; 5: 251-60.
28. Laulumaa V, Kuikka JT, Soininen H et al. Imaging of D2 dopamine receptors of patients with Parkinson's disease using single photon emission computed tomography and iodobenzamide 1123. Arch Neurol 1993; 50: 509-12.
29. Lidow MS, Goldman-Rakic PS, Rakic P et al. Dopamine D2 receptors in the cerebral cortex, distribution and pharmacological characterization with [3H]raclopride. Proc Natl Acad Sci USA 1989; 86: 6412-6.
30. Mach RH, Nader MA, Ehrenkaufer RL et al. Use of positron emission tomography to study the dynamics of psychostimulant-induced dopamine release. Pharmacol Biochem Behav 1997, 57: 477-86.
31. Martinot JL, Paillere-Martinot ML, Loc'h C et al. The estimated density of D2 striatal receptors in schizophrenia. A study with positron emission tomography and 76Br-bromolisuride. Br J Psychiatry 1991; 158: 346-50.
32. Mazière B, Loc'h C. Synthesis of radiohalogenated derivates of lisuride. J Label Comp Radiopharm 1989; 26: 100-1.
33. Meador-Woodruff JH, Damask JP, Wang J et al. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 1996; 15: 17-29.
34. Meador-Woodruff JH, Mansour A, Grandy DK et al. Distribution of D5 dopamine receptor mRNA in rat brain. Neurosci Lett 1992; 145: 209-12.
35. Moerlein SM, Banks WR, Parkinson D. Production of fluorine-18 labeled (3-N-methyl)benperidol for PET investigation of cerebral dopaminergic receptor binding. Int J Radiat Appl Instrum Part A 1992; 43: 913-7.
36. Pearlson GD, Tune LE, Wong DF et al. Quantitative D2 dopamine receptor PET and structural MRI changes in late-onset schizophrenia. Schizophr Bull 1993; 19: 783-95.
37. Pilowsky LS, Costa DC, Ell PJ et al. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry 1994; 164: 16-26.
38. Primus RJ, Thurkauf A, Xu J et al. II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel. D4 receptor-selective ligand [3H]NGD 94-1. J Pharmacol Exp Ther 1997; 282: 1020-7.
39. Reiche W, Grundmann M, Huber G. Die Dopamin(D2)-Rezeptor-SPECT mit 123I-Jodbenzamid (IBZM) in der Diagnostik des Parkmson-Syndroms. Radiologe 1995; 35: 838-43.
40. Rinne JO, Hietala J, Ruotsalainen U et al. Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride. J Cereb Blood Flow Metab 1993; 13. 310-4.
41. Rinne UK, Laihinen A, Rinne JO et al. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease Mov Disord 1990; 5: 55-9.
42. Schelosky L, Hierholzer J, Wissel J et al. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT. Mov Disord 1993, 8: 453-8.
43. Schwarz J, Tatsch K, Arnold G et al. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992; 42: 556-61.
44. Schwarz J, Tatsch K, Arnold G et al. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology 1993; 43(Suppl 6):S17-20.
45. Sedvall G, Farde L, Persson A et al. Imaging of neurotransmitter receptors in the living human brain. Arch Gen Psychiatry 1986; 43: 995-1005
46. Seeman P. Schizophrenia as a brain disease. Arch Neurol 1993; 50: 1093-7.
47. Seeman P, Corbett R, Nam D et al. Dopamine and serotonin receptors: amino acid sequences, and clinical role in neuroleptic parkinsonism. Jpn J Pharmacol 1996; 71: 187-204.
48. Seeman P, Grigonadis DE. Dopamine receptors in brain and periphery. Neurochem Int 1987; 10: 1-25.
49. Smith M, Wolf AP, Brodie JD et al. Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biol Psychiatry 1988; 23: 653-63.
50. Suzuki M, Hurd YL, Sokoloff P et al. D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 1998; 779: 58-74.
51. Tune LE, Wong DF, Pearlson G et al. Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone. Psychiatry Res 1993; 49: 219-37.
52. Van Royen E, VerhoeC NP, Speelman JD et al. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. Arch Neurol 1993; 50: 513-6.
53. Volkow ND, Wang GJ, Fowler JS et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997; 386: 830-3.
54. Wagner HN, Jr., Burns HD, Dannals RF et al. Imaging dopamine receptors in the human brain by positron tomography. Science 1983; 221: 1264-6.
55. Wang GJ, Volkow ND, Logan J et al. Evaluation of age-related changes in serotonin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. Life Sci 1995; 56: PL249-53.
56. Willner P, Muscat R, Papp M et al. Dopamine, depression and anti-depressant drugs. In: The Mesolimbic Dopamine System: From Motivation to Action. Willner P, Scheel-Krueger J (eds.). Chichester, New York, Brisbane: Wiley & Sons 387-410.
57. Wong DF, Wagner HN, Jr., Pearlson G. Dopamine receptor binding of C-11-3-N-methylspiperone in the caudate in schizophrenia and bipolar disorder: A preliminary report. Psychopharmacol Bull 1985; 21: 595-7.
58. Wong DF, Wagner HN, Jr., Tune LE et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234: 1558-63.